Skip to main content

No Differential Risk of Cutaneous Small Vessel Vasculitis with Oral Anticoagulant Use Among Patients with Atrial Fibrillation

Basic Details
Date
Type
Presentation
Materials

No Differential Risk of Cutaneous Small Vessel Vasculitis with Oral Anticoagulant Use Among Patients with Atrial Fibrillation

Information
Host

37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Related Assessment(s)
Sentinel Drug Study: Eliquis (Apixaban), Pradaxa (Dabigatran), and Xarelto (Rivaroxaban) & Cutaneous Small-Vessel Vasculitis
37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Cutaneous Small-Vessel Vasculitis following Dabigatran, Rivaroxaban, and Apixaban Use in Patients with Atrial Fibrillation: A Propensity Score Matched Analysis
Presenter(s)

Adebola Ajao, Austin Cosgrove, Efe Eworuke, Mohamed Mohamoud, Rongmei Zhang, Oren Shapira, Joy Kolonoski, John Connolly